The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: Bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy

BJU International

Volumn 96, Issue 7, 2005, Pages 1014-1018

  Nyman, Claes R ^a   Andersen, Jesper T ^a   Lodding, Per ^b   Sandin, Thorsten ^c   Varenhorst, Eberhard ^d  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c GÄVLE HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Androgen deprivation therapy; Bicalutamide; GnRH analogue; Orchidectomy; Prostate cancer

Indexed keywords

BICALUTAMIDE; GONADORELIN DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MEDICAL DECISION MAKING; ORCHIECTOMY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; SEXUALITY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ATTITUDE; FOLLOW-UP STUDIES; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 27444434261     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05802.x     Document Type: Article

References (13)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-23
2. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77
3. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-61
4. Anderson J. Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer. BJU Int 2004; 94: 758-9
5. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164: 1579-82
6. Dale J, Jatsch W, Hughes N, Pearce A, Meystre C. Information need and prostate cancer: the development of a systematic means of identification. BJU Int 2004; 94: 63-9
7. Cassileth BR, Soloway MS, Vogelzang NJ et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989; 23 (Suppl. 5): 57-62
8. Chadwick DJ, Gillat DA, Gingell JC. Medical or surgical orchidectomy: the patient's choice. BMJ 1991; 302: 572
9. Wijma C, Varenhorst E, Hjertberg H et al. Patienten kan bestämma själv: medicinsk eller kirurgisk behandling (summary in English). Prostate cancer study: Patients may choose for themselves between medical or surgical treatment. Läkartidningen 1992; 89: 1659-61
10. UICC: International Union against Cancer. In Sobin LH, Wittekind C eds, TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss 2002: 184-7
11. Sandblom G, Dufmats M, Nordenskjöld K, Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-96: results from a population-based national cancer register. South-East Region Prostate Cancer Group. Cancer 2000; 88: 1445-53
12. Auvinen A, Hakama M, Ala-Opas M et al. A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU Int 2004; 93: 52-6
13. Spetz AC, Zetterlund EL, Varenhorst E, Hammar M. Incidence and management of hot flashes in prostate cancer. J Support Oncol 2003; 1: 263-73